Evidence-based approach for prevention of radiocontrast-induced nephropathy.
The frequency of radiocontrast administration is dramatically increasing, with over 80 million doses delivered annually worldwide. Although recently developed radiocontrast agents are relatively safe in most patients, contrast nephropathy (CN) is still a major source of in-hospital and long-term morbidity and mortality, particularly in patients with preexisting kidney disease. Multiple protocols for CN prevention have been studied; however, strict guidelines have not been established, in part because of conflicting efficacy data for most prevention approaches. In this work, we critically review the major trials that have addressed common CN prophylaxis strategies, including type of radiocontrast media, N-acetylcysteine administration, extracellular fluid volume expansion, and hemofiltration/hemodialysis. We conclude with evidence-based recommendations for CN prevention, which emphasize concurrent NaHCO3 infusion and N-acetylcysteine administration. These guidelines should be helpful to hospitalists, who frequently order radiocontrast studies, and could therefore have a significant impact on prevention of CN.
Abu Jawdeh
Bassam G
BG
Department of Medicine, Case Western Reserve University School of Medicine, Rammelkamp Center for Research, Cleveland, Ohio 44109-1998, USA. bassam.abujawdeh@case.edu
Kanso
Abbas A
AA
Schelling
Jeffrey R
JR
D002986:Clinical Trials as Topic / Q000379:methods; D003287:Contrast Media / Q000009:adverse effects*; D019317:Evidence-Based Medicine / Q000379:methods*; D017052:Hospital Mortality / Q000639:trends; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000401:mortality
D003287:Contrast Media